about
Research and development of Zika virus vaccines.In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope.Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine.A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infectionComprehensive definition of human immunodominant CD8 antigens in tuberculosis.Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection.Protection of calves by a prefusion-stabilized bovine RSV F vaccine.Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells.Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection.Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection.Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice.Therapeutic vaccines for allergic disease.Protein nanovaccine confers robust immunity against Toxoplasma.Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant.An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.Protection from Hendra virus infection with Canarypox recombinant vaccine.Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium.A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies.Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.Vaccination of domestic animals with a novel oral vaccine prevents Giardia infections, alleviates signs of giardiasis and reduces transmission to humans.Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination.Newcastle disease virus-based H5 influenza vaccine protects chickens from lethal challenge with a highly pathogenic H5N2 avian influenza virus.Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection.DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections.Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells.Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines.Vaccinology in the twenty-first century.Escherichia coli-derived virus-like particles in vaccine development.A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice.A therapeutic Porphyromonas gingivalis gingipain vaccine induces neutralising IgG1 antibodies that protect against experimental periodontitis.A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination.Alpha-D-glucan nanoparticulate adjuvant induces a transient inflammatory response at the injection site and targets antigen to migratory dendritic cells.A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model.Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection.Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.Antibody therapies for the prevention and treatment of viral infections.Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine.Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model.
P1433
Q26252115-FD6C0CBA-8F48-439B-8AAC-36D2CE97E071Q27901935-26EF599B-B64D-4E05-B661-BA0F993E61F6Q30275602-e60ecadb-4bce-950c-0a03-777ac1236e21Q33894405-9F48DEBD-1788-4CE9-BA0D-9AC65A049643Q38626558-1CB9DE83-1259-424C-9B77-082A083C977DQ38849398-EA58B31E-3C01-4C27-9E4E-699ECD40958AQ41722577-422DCAE6-8D30-406D-A8D1-772D56294D4FQ41918616-A534EC14-3D0C-4041-9088-98C5929B63B4Q44170263-61D8AECA-18EB-4B76-A911-B4B72BB32FA3Q46060826-B32B1DE1-56BD-48BD-971E-B2704335C0F2Q47096633-5497A100-5CCC-4D81-AC10-3CBA0ABEE942Q47099112-EBBCA48F-3136-4B73-B908-7EF293BD0165Q47100584-06382E56-3470-4199-8B99-3609AEFAAD8FQ47102683-C52CCEE3-1C34-43EE-84B3-C75AF42DAAF4Q47105347-2F0A7356-C2E9-443C-A5B8-55D699EC999AQ47105782-4090F498-4BA1-4D43-8C38-2ABE1FA0EE11Q47105971-461A7078-E7E6-46B3-BDF0-0719BF567C40Q47106697-BA536577-22CA-449A-B95D-24A91B407A9DQ47108278-32798D5C-94C6-4B61-BDE9-BDC1673581C1Q47110427-4316F9B9-D289-491B-A2BC-66CF077AACC5Q47114163-9C7F6451-9EFD-4B8D-BC3F-5A5D5470D9A9Q47115059-86ED6836-23F8-4386-A0E0-F8BB17419761Q47117843-A5177BA0-478F-4944-AC30-D9090CEE8CB1Q47120596-C9259C6A-0E2D-491A-8A05-B4EF54CA6A07Q47125106-37845BAB-833F-4F72-9BB6-684EB7C82C4BQ47125471-95D63C5B-914C-4DF3-B379-264B3A7971F9Q47130066-E0CD8508-B67E-4AD5-9E98-BBC7B952C0A2Q47131234-7A1B9582-F446-421B-B6D5-761DDB5B9CF7Q47132009-75B054CA-8526-4BD1-BE63-943D42269893Q47132783-1BB8A908-67DE-4D6E-B963-927EF9173DFFQ47134061-87CF7202-7F58-48EB-B494-B31FDBC1967DQ47136266-A5057096-D193-4883-9CE0-CED44D1904D3Q47136777-9B550A78-D8DC-4EB2-B6AB-E05941A815B2Q47137268-B2A505E6-F623-4F18-9BB5-57BF3B6663C9Q47140392-A7F2B0C7-9641-4509-ACDC-86BEBAFA6A4EQ47141816-FBFF775A-076D-4C2D-A0D2-F8AFA286D5ADQ47142027-98BE3E45-1943-4C8D-A8A7-19693784DE5FQ47143843-3FBDF35D-6952-43A2-80EC-EFDC036DB7A3Q47146611-C002C113-5C86-4B0B-B5D1-9070279CB113Q47147430-C774DBA0-4855-4BBE-9867-2A5958040737
P1433
description
journal
@en
revista científica
@es
videnskabeligt tidsskrift
@da
wetenschappelijk tijdschrift van Macmillan Publishers
@nl
wissenschaftliche Fachzeitschrift
@de
name
npj Vaccines
@ast
npj Vaccines
@da
npj Vaccines
@en
npj Vaccines
@es
npj Vaccines
@nl
type
label
npj Vaccines
@ast
npj Vaccines
@da
npj Vaccines
@en
npj Vaccines
@es
npj Vaccines
@nl
prefLabel
npj Vaccines
@ast
npj Vaccines
@da
npj Vaccines
@en
npj Vaccines
@es
npj Vaccines
@nl
P31
P1055
P1156
21100850730
P1476
npj Vaccines
@en